New Tysabri Data Presented at 64th Annual American Academy of Neurology Meeting Highlight Biogen Idec, Inc. (Massachusetts) & Biogen Idec, Inc. (Massachusetts) Commitment to Improving Outcomes in Multiple Sclerosis

Published: Apr 27, 2012

WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced findings from several studies of TYSABRI® (natalizumab) evaluating its long-term safety and efficacy in the treatment of multiple sclerosis (MS) across the course of disease and impact on MS-related symptoms such as fatigue. These data, as well as data relating to the companies’ risk stratification algorithm as a way to help enable individual benefit risk assessment for patients with MS, were accepted for presentation at the 64th Annual Meeting of the American Academy of Neurology (AAN).

Back to news